KRAS and non-small cell lung carcinoma: Major obstacles with respect to treating NSCLC patients are mainly oncogenic mechanisms (da Cunha Santos et al., 2011), which appear in up to 40% of all LUAD cases, comprising of not yet druggable targets such KRAS (Davies et al., 2002) or fast occurring resistances against targeted and conventional therapies (Sequist et al., 2016).